There is a new world opening up in ocular therapeutics.
Eyenovia is making it possible with development programs in progressive myopia, glaucoma, mydriasis, and dry eye.
Microdose formulation technology designed to be easier, smarter, safer and better tolerated
It's a big deal
A PORTFOLIO OF CLINICAL ASSETS AND INTELLECTUAL PROPERTY
The Eyenovia clinical pipeline targets high-value eye diseases
Our intellectual property portfolio includes 8 issued/allowed and 7 pending patents in U.S. and 27 issued/allowed and 54 pending patents worldwide
Approximate Number in US Affected by Eyenovia’s Targeted Conditions*
Easier For Patients
Horizontal drug installation with less waste and spillage
Dosing reminders and tracking
Potential to reduce systemic drug exposure.
Reduced exposure to active ingredients and preservatives while maintaining efficacy
On the forefront of technology
High precision micro-dosing minimizes toxicity leading to more efficient and gentler treatment.
For quarterly updates on our progress with our phase 3 programs, or for any other questions, please provide us with your name and email address below.
Our microdosing technology is poised to transform the standard of care in ophthalmic therapeutic delivery.
295 Madison Aveue
New York, NY 10017
+1 (917) 289-1117
*1 UpToDate (2018); HCW Analyst Report (2018); Chia et. al, Am J Ophthalmol. (2014); Vitale et. al, Arch Ophthalmol, (2009); Theophanous et. al, (2018), US Census Bureau
*2 UpToDate (2018), GlobalData (2017), 2012 Fifth Edition of Vision Problems in the U.S., Friedman et. Al, Am J Ophthalmol (2004);Prostaglandin Analogues in Angle-Closure Glaucoma, Gupta et. Al, 2011; American Academy of Ophthalmology; Transparency Market Research; The Ophthalmologist; ProPublica
*3 1National Health Interview Survey, CDC (2017); Fernando A. et al., Journal of Ophthalmology (2015); Lindstrom et al., 2015; Infection control in the eyecare office (2013)
*4 2012 Gallup Poll